{"entity":{"id":"nct06157151","kind":"trial","name":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in cervical cancer, run by Precigen, Inc, now recruiting.","summary":"PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT06157151 by Precigen, Inc, with 24 participants planned, started 2025-11-11 and due to reach its primary completion in 2026-11-11. Interventions recorded: PRGN-2009 plus Pembrolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06157151","url":"https://clinicaltrials.gov/study/NCT06157151"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06157151","phase":"2","setting":"A Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.","sponsor":"Precigen, Inc","enrolled":24,"outcomes":[]},"route":"/trials/nct06157151/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}